Skip to main content
NGeneBio Co., Ltd. logo

NGeneBio Co., Ltd. — Investor Relations & Filings

Ticker · 354200 ISIN · KR7354200008 KO Professional, scientific and technical activities
Open in API
Filings indexed 343 across all filing types
Latest filing 2026-05-19 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 354200

About NGeneBio Co., Ltd.

https://www.ngenebio.com/en/index.asp

NGeneBio Co., Ltd. is a precision diagnostics company specializing in Next-Generation Sequencing (NGS) technology. The company develops and commercializes molecular diagnostic products, including in-vitro diagnostic (IVD) and companion diagnostic (CDx) solutions. Its primary focus is on oncology, offering NGS panels for the analysis of solid tumors and hematologic malignancies. Complementing its diagnostic assays, NGeneBio provides integrated bioinformatics software for comprehensive data analysis and interpretation. The company's portfolio also includes liquid biopsy technologies and personal genetic testing services, all aimed at providing precise genomic information to guide clinical decision-making.

Recent filings

Filing Released Lang Actions
증권신고서(지분증권)
Share Issue/Capital Change Classification · 85% confidence The document is a securities registration statement (“증권신고서(지분증권)”) detailing an equity offering of 7,150,000 shares and related prospectus information. It is not merely an announcement or link to a report, but the full registration/prospectus for a new share issuance. This aligns with the “Share Issue/Capital Change” category, which covers announcements and documents relating to new share issues or other capital changes.
2026-05-19 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is clearly titled 분기보고서 (Quarterly Report) for the period January 1, 2026 to March 31, 2026, and contains detailed company overview, corporate history, changes in subsidiaries, board changes, and other substantive corporate data. It is the full quarterly filing itself, not merely a notice of publication or an announcement. Therefore, it fits the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-05-15 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 72% confidence The document is an official company announcement in Korean regarding the setting of a shareholder register closing period and record date for determining rights holders for an extraordinary shareholders meeting. It does not provide financial results, audit information, or details of a formal report; rather it discloses a regulatory procedural notice. It does not fit any of the specialized categories (e.g., dividend notice, board management change, M&A, etc.) and is best classified under the general regulatory announcements fallback category.
2026-04-27 Korean
주권매매거래정지 (자본감소)
Regulatory Filings Classification · 80% confidence The document is a short regulatory announcement in Korean regarding the suspension of trading (‘주권매매거래정지’) for a listed company’s shares on KOSDAQ, citing disclosure rules and suspension period. It is not a financial report, earnings release, or detailed filing but a market trading notice under exchange regulations. This falls under the “Regulatory Filings” fallback category (RNS).
2026-04-27 Korean
주요사항보고서(감자결정)
Share Issue/Capital Change Classification · 91% confidence The document is a Korean "주요사항보고서" (Material Event Report) filed with the Financial Services Commission and Korea Exchange announcing a capital reduction decision (감자 결정), including share consolidation (3-for-1) and details on capital before/after the reduction, record dates, schedule, and legal basis. This is not a full financial report or earnings release, but a mandatory disclosure of a capital structure change (reduction and share consolidation). It therefore falls under "Share Issue/Capital Change (SHA)".
2026-04-27 Korean
주주총회소집결의 (임시주주총회)
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a formal notice of convocation for an extraordinary shareholders’ meeting (‘임시주주총회’) including the meeting date, venue, record date, board resolution date, attendance details, and agenda items (capital reduction). This aligns with materials sent to shareholders to provide meeting information and solicit votes. Therefore, it is a Proxy Solicitation & Information Statement.
2026-04-27 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.